S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
Log in

NYSE:AZNAstraZeneca Stock Price, Forecast & News

$55.34
-0.04 (-0.07 %)
(As of 08/11/2020 02:45 PM ET)
Add
Compare
Today's Range
$55.30
Now: $55.34
$55.74
50-Day Range
$52.13
MA: $55.20
$61.10
52-Week Range
$36.15
Now: $55.34
$64.94
Volume3.01 million shs
Average Volume10.90 million shs
Market Capitalization$145.23 billion
P/E Ratio66.67
Dividend Yield3.36%
Beta0.55
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More
AstraZeneca logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 1.9Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-3749-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.38 billion
Cash Flow$3.16 per share
Book Value$5.56 per share

Profitability

Net Income$1.34 billion

Miscellaneous

Employees64,400
Outstanding Shares2,624,370,000
Market Cap$145.23 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$55.34
-0.04 (-0.07 %)
(As of 08/11/2020 02:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AstraZeneca (NYSE:AZN) Frequently Asked Questions

How has AstraZeneca's stock price been impacted by Coronavirus?

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AZN shares have increased by 24.1% and is now trading at $55.34.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca
.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for AstraZeneca
.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) announced its earnings results on Thursday, July, 30th. The company reported $0.48 EPS for the quarter, beating the Zacks' consensus estimate of $0.44 by $0.04. The company earned $6.28 billion during the quarter, compared to analysts' expectations of $6.27 billion. AstraZeneca had a net margin of 8.36% and a return on equity of 37.72%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 earnings per share.
View AstraZeneca's earnings history
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semi-annual dividend on Friday, July 31st. Shareholders of record on Friday, August 14th will be given a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th.
View AstraZeneca's dividend history
.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

What price target have analysts set for AZN?

11 analysts have issued 1 year price targets for AstraZeneca's shares. Their forecasts range from $60.00 to $65.00. On average, they anticipate AstraZeneca's share price to reach $61.67 in the next year. This suggests a possible upside of 11.4% from the stock's current price.
View analysts' price targets for AstraZeneca
.

Has AstraZeneca been receiving favorable news coverage?

News headlines about AZN stock have been trending neutral this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about AstraZeneca
.

Are investors shorting AstraZeneca?

AstraZeneca saw a increase in short interest in February. As of February 15th, there was short interest totaling 7,840,000 shares, an increase of 15.0% from the January 31st total of 6,820,000 shares. Based on an average daily volume of 2,860,000 shares, the days-to-cover ratio is presently 2.7 days.
View AstraZeneca's Short Interest
.

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), AT&T (T), Advanced Micro Devices (AMD), Moderna (MRNA) and Cisco Systems (CSCO).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.49%), Fisher Asset Management LLC (0.64%), Raymond James & Associates (0.05%), Hardman Johnston Global Advisors LLC (0.03%), Thornburg Investment Management Inc. (0.03%) and Russell Investments Group Ltd. (0.03%).
View institutional ownership trends for AstraZeneca
.

Which institutional investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Hardman Johnston Global Advisors LLC, Janney Capital Management LLC, ZWJ Investment Counsel Inc., Synovus Financial Corp, Candriam Luxembourg S.C.A., PNC Financial Services Group Inc., and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for AstraZeneca
.

Which institutional investors are buying AstraZeneca stock?

AZN stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Jennison Associates LLC, James Investment Research Inc., Raymond James & Associates, CWM LLC, Trillium Asset Management LLC, Trexquant Investment LP, and Barnett & Company Inc..
View insider buying and selling activity for AstraZeneca
.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $55.34.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $145.23 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.